Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Gastrointest Cancer ; 54(1): 62-66, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35000070

RESUMO

PURPOSE: Colorectal cancer (CRC) is the third most common cancer in the world, with enhancing morbidity and mortality each year. Due to the drug resistance against CRC, the use of novel compounds besides chemotherapy is required. Natural seafood contains large amounts of biologically active substances with new chemical structures and new medicinal activities. The aim of this study was to evaluate the effects of hydroalcoholic extract of Sargassum oligocystom algae on SW742, HT-29, WiDr, and CT-26 CRC cell lines, and to evaluate the expression of P53 and APC genes using quantitative real-time PCR (RT-qPCR). METHODS: The cytotoxicity of S. oligocystom hydroalcoholic extract was determined by MTT and trypan blue methods in six different concentrations including 0.1, 0.2, 0.5, 1, 2, and 4 mg/mL on various CRC cell lines and a control group. The expression of P53 and APC genes in exposure to 2 mg/mL of the extract was also evaluated using RT-qPCR. RESULTS: The LD50 and LD90 of S. oligocystom included 0.5-1 and > 2 mg/mL, respectively mostly affecting SW742 and CT-26 cells. In the trypan blue test, 90% viability and death of cells were observed at 0.1 and 4 mg/mL of extract, respectively. The 2 mg/mL was a safe cytotoxic concentration. A significant viability decrease was observed at concentrations ≥ 1 mg/mL (p < 0.001). Sargassum oligocystom extract at 2 mg/mL significantly increased the expression of APC ranging 1.98-2.2-fold (p < 0.001) but not P53 gene which ranged 0.5-0.68-fold (p = 0.323) after 24 h. CONCLUSION: These results indicated that the brown algae S. oligocystom extract had significant antitumor effects against the SW742, HT-29, WiDr, and CT-26 CRC cell lines and especially CT-26, suggesting that it may be a potential candidate for further studies and therefore designing drugs of natural anticancer origin. The S. oligocystom had an anticancer effect via an increase in the APC gene expression.


Assuntos
Neoplasias Colorretais , Sargassum , Humanos , Apoptose , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/genética , Neoplasias Colorretais/patologia , Genes APC , Células HT29 , Sargassum/química , Tomografia Computadorizada por Raios X , Azul Tripano/farmacologia , Azul Tripano/uso terapêutico
2.
Mol Med Rep ; 26(1)2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35621135

RESUMO

The prognosis of glioblastoma, which is the most frequent type of adult­onset malignant brain tumor, is extremely poor. Therefore, novel therapeutic strategies are needed. Previous studies report that JCI­20679, which is synthesized based on the structure of naturally occurring acetogenin, inhibits mitochondrial complex I and suppresses the growth of various types of cancer cells. However, the efficacy of JCI­20679 on glioblastoma stem cells (GSCs) is unknown. The present study demonstrated that JCI­20679 inhibited the growth of GSCs derived from a transposon system­mediated murine glioblastoma model more efficiently compared with the growth of differentiation­induced adherent cells, as determined by a trypan blue staining dye exclusion test. The inhibition of proliferation was accompanied by the blockade of cell­cycle entry into the S­phase, as assessed by a BrdU incorporation assay. JCI­20679 decreased the mitochondrial membrane potential, suppressed the oxygen consumption rate and increased mitochondrial reactive oxygen species generation, indicating that JCI­20679 inhibited mitochondrial activity. The mitochondrial inhibition was revealed to increase phosphorylated (phospho)­AMPKα levels and decrease nuclear factor of activated T­cells 2 (NFATc2) expression, and was accompanied by a decrease in calcineurin phosphatase activity. Depletion of phospho­AMPKα by knockdown of AMPKß recovered the JCI­20679­mediated decrease in NFATc2 expression levels, as determined by western blotting and reverse transcription­quantitative PCR analysis. Overexpression of NFATc2 recovered the JCI­20679­mediated suppression of proliferation, as determined by a trypan blue staining dye exclusion test. These results suggest that JCI­20679 inhibited mitochondrial oxidative phosphorylation, which activated AMPK and reduced NFATc2 expression levels. Moreover, systemic administration of JCI­20679 extended the event­free survival rate in a mouse model transplanted with GSCs. Overall, these results suggested that JCI­20679 is a potential novel therapeutic agent against glioblastoma.


Assuntos
Glioblastoma , Proteínas Quinases Ativadas por AMP/metabolismo , Animais , Proliferação de Células , Glioblastoma/tratamento farmacológico , Glioblastoma/genética , Glioblastoma/metabolismo , Camundongos , Células-Tronco Neoplásicas/metabolismo , Azul Tripano/metabolismo , Azul Tripano/uso terapêutico
3.
Acta Ophthalmol ; 100(2): e598-e608, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33998147

RESUMO

PURPOSE: To report the long-term outcomes of large diameter epiretinal lyophilized amniotic membranes (lAMs) in recurrent or persistent macular holes (MHs) with or without rhegmatogenous retinal detachment (RRD), in a prospective interventional case series. METHODS: Ten eyes of 10 patients underwent pars plana vitrectomy for MH-associated RRD (n = 5) or persistent MH without RRD (n = 5), in a university Hospital. A 3 or 4 mm diameter disc of lAM, stained with 0.06% trypan blue, was inserted with a catheter through a sclerotomy and positioned over the MH. Gas or silicone-oil tamponade was used. At 1 year, the main outcome was anatomic success defined as complete MH closure. Secondary outcomes were best corrected visual acuity (BCVA) recovery, changes in ellipsoid zone (EZ) and external limiting membrane (ELM) defects, complications. Mean follow-up was 13.8 ± 2.9 months (range, 12-18). RESULTS: Mean baseline data were minimum and maximum diameters, respectively, 945 ± 330 and 1507 ± 717 µm; axial length 26.58 ± 3.38 mm; and number of prior surgeries 1.4 ± 0.96. At 1 year, anatomic success was achieved in eight eyes (80%), and two had reduced diameter of MH. All RRDs were reattached without recurrence. Mean logMAR BCVA improved from 1.92 ± 0.58 to 1.17 ± 0.57 (p < 0.001), with nine eyes (90%) achieving ≥0.3 logMAR improvement. Mean EZ and ELM defects decreased (p = 0.004, p = 0.003, respectively). Postoperative complications were RRD (n = 1) reattached by subsequent surgery, lAM slightly retracted under silicone (n = 1), foveal atrophy after early lAM displacement (n = 1). CONCLUSION: A 1-year follow-up highlighted that epiretinal large discs of blue-stained lAM can help safely close refractory MHs, and provide satisfactory visual recovery.


Assuntos
Perfurações Retinianas/cirurgia , Azul Tripano/uso terapêutico , Vitrectomia/métodos , Idoso , Âmnio/transplante , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Perfurações Retinianas/diagnóstico por imagem , Perfurações Retinianas/patologia
4.
Int Immunopharmacol ; 81: 106263, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32028243

RESUMO

Pathological ß-amyloid (Aß)-induced microglial activation could cause chronic neuroinflammation in the brain of Alzheimer's disease (AD) patients, and has been considered as one of the main pathological events of this disease. Chicago sky blue 6B (CSB6B), a pigment used in biochemical staining, has been reported to produce analgesic effects in neuroinflammatory-associated pain models. We have previously found that CSB6B could directly inhibit Aß aggregation and prevent Aß toxicity in neurons. However, it remains unclear whether this compound could prevent Aß-induced neuroinflammation and impairments of learning and memory in the AD models. In this study, CSB6B was found to effectively inhibit the production of pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-1ß, without affecting cell viability in BV2 microglia cells stimulated by Aß oligomer and lipopolysaccharide. Moreover, CSB6B significantly reduced mRNA expression of inducible nitric oxide synthase and increased mRNA expression of arginase-1, suggesting that CSB6B might promote the polarization of BV2 cells into M2 phenotype. In Aß oligomer-treated mice, hippocampal injection of CSB6B prevented cognitive impairments, and attenuated pro-inflammatory cytokines production. In addition, CSB6B inhibited nuclear transcription factor-κB (NF-κB), and restrainedthe activation of NOD-like receptor pyrin domain containing-3 (NLRP3) both in vitro and in vivo. According to our results, CSB6B may counteract Aß-induced cognitive impairments and neuroinflammation by inhibiting NF-κB and NLRP3. Combined with previous studies, we anticipated that CSB6B may further develop into a potential anti-AD drug with multiple functions on neurons and microglia cells, concurrently.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Disfunção Cognitiva/tratamento farmacológico , Microglia/metabolismo , Inflamação Neurogênica/tratamento farmacológico , Neurônios/metabolismo , Azul Tripano/uso terapêutico , Peptídeos beta-Amiloides/imunologia , Animais , Linhagem Celular , Citocinas/metabolismo , Humanos , Mediadores da Inflamação/metabolismo , Camundongos , Camundongos Endogâmicos ICR , Microglia/patologia , NF-kappa B/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Neurônios/patologia , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo II/metabolismo
5.
J Bras Nefrol ; 41(3): 315-322, 2019.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30720852

RESUMO

INTRODUCTION: It is hypothesized that increased macrophage migration inhibitory factor (MIF) expression may contribute to diabetic nephropathy (DN) pathogenesis. The aim of the present study was to investigate the renal effects of MIF inhibition in a diabetic experimental model. METHODS: Eighteen male Wistar rats (230 ± 20 g) were divided into three groups: 1) control, 2) diabetic (STZ, 50 mg/kg, dissolved in saline, ip), 3) diabetic + MIF antagonist (p425, 1 mg/kg per day, ip, on the 21th day, for 21 consecutive days). The treatment started since we founwd a significant increase in urine albumin excretion (UAE) rate in the diabetic rats in comparison with the control rats. The rats were kept individually in metabolic cages (8 AM-2 PM) and urine samples were collected in the 21 and 42th day. At the end, blood and tissue samples were collected for biochemical (BS, UPE, urine GAG, BUN, Cr, Na, and K) and histological analyses. RESULTS: The results of this study showed that MIF antagonist (p425) significantly decreased urine protein and GAG excretion, urine protein/creatinine ratio, and serum BUN and Cr in the streptozotocin-induced DN in the rats. Pathological changes were significantly alleviated in the MIF antagonist (p425)-administered DN rats. CONCLUSION: Collectively, these data suggested that MIF antagonist (p425) was able to protect against functional and histopathological injury in the DN.


Assuntos
Diabetes Mellitus Experimental/patologia , Nefropatias Diabéticas/tratamento farmacológico , Oxirredutases Intramoleculares/antagonistas & inibidores , Fatores Inibidores da Migração de Macrófagos/antagonistas & inibidores , Substâncias Protetoras/farmacologia , Substâncias Protetoras/uso terapêutico , Azul Tripano/farmacologia , Azul Tripano/uso terapêutico , Albuminúria/tratamento farmacológico , Animais , Glicemia , Creatinina/sangue , Creatinina/urina , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/urina , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/patologia , Nefropatias Diabéticas/urina , Modelos Animais de Doenças , Glicosaminoglicanos/urina , Rim/patologia , Ativação de Macrófagos , Masculino , Ratos , Ratos Wistar , Estreptozocina/farmacologia
6.
Clin Hemorheol Microcirc ; 69(1-2): 327-336, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29630545

RESUMO

BACKGROUND: Drug-induced liver injury (DILI) is the most common reason for withdrawal of anticancer drugs from the market. To prevent adverse side effects of drugs, it is important to investigate potential toxicity in vitro. However, outcome of cytotoxicity screenings can differ remarkably depending on the method used. OBJECTIVE: We aimed to compare XTT, ATP-based CellTiter-Glo®2.0 and trypan blue exclusion (TBE) assays regarding their sensitivity in detecting acute cytotoxicity on HepG2 cells after incubation with the classical anticancer drugs Taxol and Imatinib or with the proteasome inhibitor MG-132. METHODS: HepG2 cells were treated for 48 h and cell viability was analysed by XTT, CellTiter-Glo®2.0 or TBE assay. RESULTS: All tested compounds showed a reduction of viability of HepG2 cells. However, assay results differed significantly: Both ATP-based and TBE assay showed concentration-dependent cytotoxic effects, but outcomes were less pronounced with TBE. In contrast, the widely used XTT assay did not detect any acute cytotoxicity of Taxol and Imatinib. CONCLUSIONS: Acute cytotoxic effects of tested compounds could be revealed. However, results were significantly different from each other with ATP assay being the most sensitive one under the conditions tested. Thus, acute cytotoxicity can be dramatically underestimated if only standard XTT test is used.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Carcinoma Hepatocelular/tratamento farmacológico , Mesilato de Imatinib/farmacologia , Neoplasias Hepáticas/tratamento farmacológico , Paclitaxel/farmacologia , Inibidores de Proteassoma/farmacologia , Azul Tripano/uso terapêutico , Antineoplásicos/farmacologia , Bioensaio , Carcinoma Hepatocelular/patologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Humanos , Neoplasias Hepáticas/patologia
7.
J Cataract Refract Surg ; 42(12): 1774-1778, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-28007109

RESUMO

PURPOSE: To study the effect of trypan blue on lens capsule elasticity and ease of completing a continuous curvilinear capsulorhexis (CCC) in a sheep lens model and to subsequently observe the effects of trypan blue in the surgical setting of 3 pediatric patients. SETTING: State University of New York, Downstate Medical Center, Brooklyn, New York, USA. DESIGN: Prospective case series. METHODS: Twenty-four lenses were excised from fresh sheep globes. Twelve lenses were immersed in trypan blue for 2.5 minutes, and 12 lenses were immersed in a balanced salt solution for 2.5 minutes. Ease of completion of CCC was graded, and intralenticular pressure was quantified. A pediatric cataract surgeon used trypan blue to stain the lens capsules of 3 children during cataract surgery. The surgeon noted the effects of trypan blue on capsule elasticity and on the ease of completion of the CCC. RESULTS: Lenses immersed in trypan blue had a mean score of 2.58 in ease of completion of capsulorhexis compared with the control group (1.5) (P = .031). Capsulorhexis was successfully completed in 91.7% of trypan blue cases compared with 58.3% of controls. Immersion in trypan blue decreased the intralenticular pressure by a mean of 4.5 mm Hg (P = .025). Successful capsulorhexis was completed in the 3 pediatric cases. CONCLUSION: Trypan blue improved the success rate of CCC completion in the sheep lens by decreasing lens capsule elasticity. FINANCIAL DISCLOSURE: None of the authors has a financial or proprietary interest in any material or method mentioned.


Assuntos
Capsulorrexe/métodos , Corantes/uso terapêutico , Azul Tripano/uso terapêutico , Animais , Catarata , Criança , Humanos , Modelos Animais , Estudos Prospectivos , Coloração e Rotulagem
8.
Biotech Histochem ; 89(8): 564-7, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24867494

RESUMO

Trypan blue is colorant from the 19(th) century that has an association with Africa as a chemotherapeutic agent against protozoan (Trypanosomal) infections, which cause sleeping sickness. The dye still is used for staining biopsies, living cells and organisms, and it also has been used as a colorant for textiles.


Assuntos
Coloração e Rotulagem/métodos , Têxteis , Azul Tripano/química , Azul Tripano/uso terapêutico , Tripanossomíase Africana/tratamento farmacológico , Animais , Antiprotozoários/efeitos adversos , Antiprotozoários/uso terapêutico , Corantes/efeitos adversos , Corantes/uso terapêutico , Humanos , Azul Tripano/efeitos adversos
9.
Biotech Histochem ; 85(6): 341-54, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21080764

RESUMO

Trypanosomiasis, a group of diseases including sleeping sickness in humans and Nagana in cattle in Africa, and Chagas' disease in South America, remains a considerable problem in the 21(st) century. The therapies that are available, however, usually have their roots in the "dye therapy" of a century ago, knowledge gained at the microscope from parasite staining procedures and converted to chemotherapy based on compounds closely related to the laboratory reagents. Dyes such as trypan red and trypan blue led to the development of suramin, while cationic nitrogen heterocyclic dyes furnished examples of the phenanthridinium class, such as ethidium (homidium) and isometamidium. Both suramin and isometamidium remain in use. Owing to mutagenicity issues, the presence of ethidium among the phenanthridinium dyes has led to concerns over the clinical use of related derivatives. There are several mechanisms for dye-DNA interaction, however, including possible hydrogen bonding of dye to the polymer, and these are discussed together with structure-activity relations and cellular localization of the phenanthridine and isomeric acridines involved. Better understanding of nucleic acid binding properties has allowed the preparation of more effective phenanthridinium analogues intended for use as anticancer/antiviral therapy.


Assuntos
Doença de Chagas/tratamento farmacológico , DNA/química , Fenantridinas/química , Fenantridinas/uso terapêutico , Tripanossomicidas/história , Tripanossomíase Africana/tratamento farmacológico , Acridinas/química , Acridinas/história , Acridinas/uso terapêutico , África , Animais , Compostos Azo/uso terapêutico , Bovinos , História do Século XIX , História do Século XX , Humanos , Ligação de Hidrogênio , Substâncias Intercalantes/química , Substâncias Intercalantes/história , Substâncias Intercalantes/uso terapêutico , Fenantridinas/história , América do Sul , Suramina/química , Suramina/uso terapêutico , Azul Tripano/uso terapêutico , Tripanossomicidas/uso terapêutico , Trypanosoma congolense/efeitos dos fármacos , Trypanosoma cruzi/efeitos dos fármacos
10.
Retina ; 29(8): 1111-8, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19491726

RESUMO

PURPOSE: To assess whether reading ability and microperimetry improve as demonstrated for visual acuity after surgery for macular hole and macular pucker. METHODS: Fifty-nine consecutive patients underwent pars plana vitrectomy for macular pucker (n = 41) or full-thickness macular holes (n = 18). Functional assessment was made at 3, 6, and 12 months after surgery and included far visual acuity (Early Treatment Diabetic Retinopathy Study charts), retinal sensitivity using the microperimeter (MP1, Nidek Technologies, Padova, Italy), and reading ability (MNRead charts). RESULTS: An improvement was recorded both for macular holes and puckers not only for visual acuity, but also for reading acuity and mean central retinal sensitivity (P < 0.01 for the overall comparisons between baseline and follow-up values). Maximum reading speed was already good at baseline both for puckers and holes overall, and a significant mean improvement was recorded only in patients with macular hole at 6 and 12 months (P < 0.01). Although eyes with macular holes had worse baseline visual function compared with puckers (P < 0.01 for all measures of visual function except for reading speed), they recovered to similar levels thanks to greater improvement (P < 0.05 for the difference in improvement during follow-up between puckers and holes for all measures of visual function). No differences were found among indocyanine green or trypan blue staining compared with no staining for internal limiting membrane removal based on all outcome measures (P > 0.05 for the overall difference of visual function improvement during follow-up). CONCLUSION: The improvement found for visual acuity after vitrectomy for macular hole and pucker also regards retinal sensitivity and reading ability for up to 12 months. This is reassuring concerning the benefits for the patients, and this shows that visual acuity is a valid functional measure for investigating the efficacy of macular surgery.


Assuntos
Leitura , Retina/fisiologia , Perfurações Retinianas/cirurgia , Idoso , Corantes/uso terapêutico , Humanos , Verde de Indocianina/uso terapêutico , Qualidade de Vida , Retina/cirurgia , Perfurações Retinianas/psicologia , Resultado do Tratamento , Azul Tripano/uso terapêutico , Acuidade Visual , Vitrectomia/métodos
11.
J Fr Ophtalmol ; 30(9): 914-7, 2007 Nov.
Artigo em Francês | MEDLINE | ID: mdl-18046275

RESUMO

OBJECTIVE: To study the results of phacoemulsification in eyes with white cataract using trypan blue for capsule staining. PATIENTS AND METHODS: Thirty patients who had white cataract were included in this prospective study. They had phacoemulsification and continuous curvilinear capsulorhexis using trypan blue. Intraoperative problems related to capsulorhexis and phacoemulsification as well as postoperative outcomes where analyzed. Postoperative examinations were done at 1 day, 1 week, and 1, 3, 6, and 12 months. The mean follow-up was 10 months. RESULTS: Complet capsulorhexis was achieved in 26 cases. Intraoperative complications included incomplet capsulorhexis in four cases (13.3%) and conversion to a conventional extraction technique in two cases. There were no cases of posterior capsular tear. Twenty-eight eyes (93.3%) had a final best corrected visual acuity at 8/10 or better. Postoperative complications included moderate transient corneal edema in six cases (20%) and iritis in three cases (10%). There were no complications related to the use of trypan blue. CONCLUSION: Phacoemulsification using trypan blue was safe and effective in managing white cataract and had a high success rate.


Assuntos
Capsulorrexe/métodos , Corantes/uso terapêutico , Facoemulsificação/métodos , Azul Tripano/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Catarata/classificação , Catarata/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Facoemulsificação/efeitos adversos , Estudos Prospectivos , Resultado do Tratamento , Acuidade Visual
13.
J Cataract Refract Surg ; 31(10): 1867-9, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16338552

RESUMO

Use of trypan blue for penetrating keratoplasty was developed to facilitate the procedure. Trypan blue is injected before and after the addition of 0.25 mL of an ophthalmic viscosurgical device (OVD), sodium hyaluronate, to stain the internal and external cut edge of the cornea as well as the OVD, enabling the surgeon to improve visualization of the incision and suture depth, improve alignment of host and donor tissues, and ensure that all OVD is removed.


Assuntos
Corantes/uso terapêutico , Ceratoplastia Penetrante/métodos , Azul Tripano/uso terapêutico , Corantes/administração & dosagem , Humanos , Ácido Hialurônico/uso terapêutico , Injeções , Coloração e Rotulagem , Técnicas de Sutura , Azul Tripano/administração & dosagem
14.
Arq. bras. oftalmol ; 64(4): 333-335, jul.-ago. 2001. tab
Artigo em Inglês | LILACS | ID: lil-292584

RESUMO

Purpose: To describe the use of anterior capsule staining in cataracts without red reflex using a 0.025 percent trypan blue solution. Methods: Six eyes of 6 patients with cataracts without red reflex were submitted to phacoemulsification using a direct injection of 0.2 to 0.5 ml of 0.025 percent trypan blue in the anterior chamber previous to viscoelastic injection. All patients had an ophthalmologic examination prior to surgery, as well as pre and postoperative corneal endothelial cell count. Results:In all cases the capsule became stained with a faint blue color that enabled an adequate visibility of the flap during the continuous curvilinear anterior capsulotomy (CCC). There were no i I II or postoperative complications. The endothelial cell loss varied between 1.8 percent and 26.6 percent (mean 12.8 percent). Conclusion: Staining the anterior capsule with 0.025 percent trypan blue solution allows a good visibility of the capsular flap and facilitates the confection of CCC in cataracts without red reflex.


Assuntos
Humanos , Pessoa de Meia-Idade , Cápsula do Cristalino/cirurgia , Extração de Catarata/métodos , Azul Tripano/uso terapêutico , Dispositivos de Proteção dos Olhos , Facoemulsificação/métodos , Lentes Intraoculares
15.
J S Afr Vet Assoc ; 67(2): 77-82, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8765067

RESUMO

It has been suggested that the antibabesial drug diminazene causes a rapid decline in haematocrit after treatment of dogs with high Babesia canis parasitaemias, compared with trypan blue. To test this, 19 dogs with clinically mild to moderate, uncomplicated babesiosis were placed in low, moderate or high parasitaemia groups, based on venous parasitaemias, and were allotted randomly to diminazene or trypan blue treatment groups. Haematocrit and parasitaemia were determined before treatment, and at 2, 6, 12, 18 and 24 hours. The drugs were compared for effects on haematocrit and parasite clearance. Changes in haematocrit after treatment were analysed. There were no significant differences between diminazene and trypan blue for haematocrit or parasite clearance. There was no correlation between initial parasitaemia and initial or post-treatment haematocrit. In all dogs, haematocrit fell following treatment. The maximum mean reduction from the baseline (0 h) was 0.046 l/l (range 0.02-0.07 l/l); this most often occurred at 6 or 12 h. The 24 h haematocrit ranged from 70.5-113.6% of baseline (mean absolute haematocrit 0.019 l/l below baseline). All dogs improved clinically during the study period. It was concluded that either diminazene or trypan blue can be safely used to treat dogs with clinically mild or moderate, uncomplicated babesiosis. Parasitaemia need not be taken into account when deciding which antibabesial drug to administer and does not appear to be related to the degree of anaemia.


Assuntos
Babesiose/tratamento farmacológico , Diminazena/uso terapêutico , Doenças do Cão/tratamento farmacológico , Hematócrito/veterinária , Parasitemia/tratamento farmacológico , Azul Tripano/uso terapêutico , Tripanossomicidas/uso terapêutico , Análise de Variância , Animais , Babesiose/sangue , Temperatura Corporal , Diminazena/economia , Doenças do Cão/sangue , Cães , Parasitemia/sangue , Análise de Regressão , Azul Tripano/economia , Tripanossomicidas/economia
16.
Lasers Surg Med ; 12(4): 450-8, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1495373

RESUMO

Little attention has been given to the bactericidal effect of laser irradiation, particularly using low-power energy lasers. It has been demonstrated that He-Ne laser light has an inhibitory action on dental plaque. The purpose of this study was to investigate the bactericidal effect of He-Ne laser irradiation on cariogenic microorganisms. The bactericidal effect was determined by the formation of a growth-inhibitory zone or by the counting of viable bacterial colonies. Streptococcus sobrinus AHT that is a Gram-positive microorganism was sensitive to He-Ne laser light, but Escherichia coli, a Gram-negative microorganism, was resistant. The effect of several dyes necessary to instigate a bactericidal action was also examined. A growth-inhibitory zone was observed using 10 kinds of blue, purple, or green dyes, which were mainly phenylmethane dyes. The leakage of potassium from S. sobrinus AHT following laser irradiation was determined using an atomic absorption spectrophotometer. The leakage began to increase following irradiation for 2 min, and reached a plateau following irradiation for 30-60 min. Moreover, to examine some changes in the dye itself following laser irradiation in the absence of bacteria, ultraviolet-visible absorption spectra and 1H NMR spectra were recorded. In this study, it was indicated that the bactericidal effect on cariogenic bacteria by He-Ne laser irradiation was efficient only in the presence of specific dyes. It is suggested that this laser may be suitable for clinical applications in preventive dentistry.


Assuntos
Corantes/uso terapêutico , Terapia a Laser , Radiossensibilizantes/uso terapêutico , Streptococcus/efeitos da radiação , Contagem de Colônia Microbiana , Cárie Dentária/microbiologia , Deutério , Escherichia coli/crescimento & desenvolvimento , Escherichia coli/metabolismo , Escherichia coli/efeitos da radiação , Violeta Genciana/uso terapêutico , Hélio , Humanos , Espectroscopia de Ressonância Magnética , Neônio , Potássio/farmacocinética , Espectrofotometria Ultravioleta , Streptococcus mutans/crescimento & desenvolvimento , Streptococcus mutans/metabolismo , Streptococcus mutans/efeitos da radiação , Streptococcus sobrinus/crescimento & desenvolvimento , Streptococcus sobrinus/metabolismo , Streptococcus sobrinus/efeitos da radiação , Fatores de Tempo , Azul Tripano/uso terapêutico
18.
J S Afr Vet Assoc ; 50(4): 346-52, 1979 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-553976

RESUMO

The therapeutic regime used in the treatment of dogs with Babesia canis infection differed between dogs with mild (uncomplicated) and severe (complicated) disease. In addition to the treatment given to dogs with mild disease, the dogs with severe disease received intravenous fluids, heparin and blood transfusion together with other supportive measures. Mortalities occurred only in the group with severe disease and were attributed to disseminated intravascular coagulation.


Assuntos
Amidinas/uso terapêutico , Antiprotozoários/uso terapêutico , Babesiose/terapia , Benzamidinas/uso terapêutico , Diminazena/uso terapêutico , Doenças do Cão/terapia , Éteres Fenílicos/uso terapêutico , Azul Tripano/uso terapêutico , Doença Aguda , Animais , Babesiose/tratamento farmacológico , Diminazena/análogos & derivados , Coagulação Intravascular Disseminada/complicações , Cães , Quimioterapia Combinada , Infusões Parenterais
19.
Invest Urol ; 15(6): 496-7, 1978 May.
Artigo em Inglês | MEDLINE | ID: mdl-649301

RESUMO

A single intraperitoneal injection of sodium oxalate was used to induce intrarenal tubular precipitation of calcium oxalate in rats. This experimental model was used to screen the efficacy of hydrochlorothiazide, orthophosphate, methylene blue, trypan blue, retinal folic acid, neuraminidase, and lysozyme in retarding intratubular calcium oxalate precipitation. Orthophosphate caused a 53 per cent reduction in calcium oxalate precipitation relative to the control animals.


Assuntos
Cálculos Urinários/tratamento farmacológico , Animais , Cálcio , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Feminino , Ácido Fólico/uso terapêutico , Hidroclorotiazida/uso terapêutico , Azul de Metileno/uso terapêutico , Muramidase/uso terapêutico , Neuraminidase/uso terapêutico , Oxalatos , Fosfatos , Ratos , Azul Tripano/uso terapêutico , Vitamina A/uso terapêutico
20.
Int J Cancer ; 17(1): 82-9, 1976 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-1248902

RESUMO

Systemic administration of the synthetic immunopotentiator pyran, was as effective as the use of the biologic immunopotentiator BCG in activating macrophages and in inhibiting the Lewis lung carcinoma and MCA 2182 sarcoma. Several other synthetic polyanions also activated macrophages and exhibited some anti-tumor activity, but none were as effective as pyran. Cell-wall fractions such as the Ribi vaccine and MER were considerably less effective than BCG. The anti-tumor activity of pyran against the virtually non-immunogenic Lewis lung carcinoma involved non-specifically activated macrophages, and both anti-tumor activity and macrophage activating ability persisted over a 100-fold range of drug from 0.5 mg/kg to 50 mg/kg. The ability of activated macrophages to destroy tumor cells was abrogated by treatment with trypan blue, an inhibitor of macrophage lysosomal enzymes. In addition, preincubation of tumor cells with activated peritoneal cells at effector-cell:target-cell ratios of 20:1 and 5:1 markedly decreased tumor incidence and mortality. Glycogen-stimulated or unstimulated peritoneal cells were completely inactive in inhibiting tumor growth in vivo or exhibiting cytotoxicity in vitro, demonstrating the requirement for activated macrophages selective for tumor-cell destruction.


Assuntos
Vacina BCG/farmacologia , Transformação Celular Neoplásica/efeitos dos fármacos , Neoplasias Pulmonares/tratamento farmacológico , Macrófagos/imunologia , Piranos/farmacologia , Sarcoma Experimental/tratamento farmacológico , Animais , Vacina BCG/uso terapêutico , Linhagem Celular , Neoplasias Pulmonares/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Transplante de Neoplasias , Neoplasias Experimentais/tratamento farmacológico , Piranos/uso terapêutico , Sarcoma Experimental/imunologia , Azul Tripano/farmacologia , Azul Tripano/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...